StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Gilead Sciences (GILD) PT Lowered to $87 at Cantor Fitzgerald
February 12, 2019 7:14 AM
Cantor Fitzgerald analyst Alethia Young lowered the price target on Gilead Sciences (NASDAQ ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst PT Change
Next Articles
Gilead Sciences (GILD) NASH Expectations Were Low, RBC Says; PT Trimmed to $84
February 12, 2019 6:53 AM
Gilead Sciences's (GILD) STELLAR Failure Was Expected, Reit Neutral At Baird
February 12, 2019 6:39 AM
Gilead (GILD) calls active into late stage NASH study fails
February 12, 2019 4:58 AM
Options expected to have increasing volume: CHGG EA MGI GILD TAP NVDA KO
February 12, 2019 4:31 AM
UPDATE: Citi Downgrades Gilead Sciences (GILD) to Neutral
February 12, 2019 2:50 AM
UPDATE: Wells Fargo Downgrades Gilead Sciences (GILD) to Market Perform
February 12, 2019 1:33 AM
After-Hours Movers 02/11: (RLGT) (CHGG) (VKTX) Higher; (VRNS) (LABL) (CMP) (more...)
February 11, 2019 5:27 PM
Gilead Sciences (GILD) Falls 4% After-Hours Following Failure of Cirrhosis Study
February 11, 2019 4:33 PM
Gilead Sciences (GILD) Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to NASH Doesn't Meet Primary Endpoint
February 11, 2019 4:32 PM
Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
February 11, 2019 4:30 PM
Call Buying Activity in Gilead Sciences (GILD) Highlights 'Speculative Bullish Sentiment' in Shares -Susquehanna
February 11, 2019 1:55 PM
